Senseonics【SENS】銘柄情報

Senseonics Holdings Inc (SENS) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

5.94

( - )

買値

5.75

売値

6.00

出来高

0.00 日の範囲 0.00

4.79 52 週間の範囲 8.75

時価総額

310.086M

前日終値

5.94

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 830,384

発行済株式数

52,202,965

配当利回り

PER

-2.89

1 株当たり利益 (EPS)

-1.98

歳入

40.71M

純利益

-87.19M

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversen... Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. 詳細を表示

セクター

Healthcare

業界

Medical Equipment & Supplies

ウェブサイト

www.senseonics.com

本社

Germantown, United States

設立

1996

Senseonics Holdings Inc is listed in the Healthcare sector of the ナスダック市場 with ticker SENS. The last closing price for Senseonics was US$5.94. Over the last year, Senseonics shares have traded in a share price range of US$ 4.79 to US$ 8.75.

Senseonics currently has 52,202,965 shares in issue. The market capitalisation of Senseonics is US$310.09 million. Senseonics has a price to earnings ratio (PE ratio) of -2.89.

Form 4 - Statement of changes in beneficial ownership of securities

Senseonics and Welldoc Partner to Develop Next-Generation App for Eversense® 365

The new app will offer an enhanced user experience and exciting new features, including improved integration...

Form 8-K - Current report

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.26	-4.1935483871	6.2	6.4202	5.33	1662907	5.7281432	CS
4	-0.9	-13.1578947368	6.84	7.6943	5.33	873336	6.36586249	CS
12	-0.66	-10	6.6	7.6943	4.79	872010	5.89246534	CS
26	0.29	5.13274336283	5.65	8.75	4.79	667483	6.29879494	CS
52	0.05	0.848896434635	5.89	8.75	4.79	618919	6.27845664	CS
156	0.05	0.848896434635	5.89	8.75	4.79	618919	6.27845664	CS
260	0.05	0.848896434635	5.89	8.75	4.79	618919	6.27845664	CS